New hope for stem cell patients: simpler drug combo may cut severe side effects

NCT ID NCT06252870

First seen Feb 01, 2026 · Last updated May 24, 2026 · Updated 11 times

Summary

This study tests whether a single drug (cyclophosphamide) given after a stem cell transplant can prevent graft-versus-host disease (GVHD) as well as standard multiple-drug approaches. About 82 adults with blood cancers will receive one of two conditioning regimens before transplant, then only cyclophosphamide and methotrexate afterward. The goal is to reduce severe GVHD while improving recovery and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Angers

    RECRUITING

    Angers, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU Brest

    RECRUITING

    Brest, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU Nantes

    RECRUITING

    Nantes, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.